ReviewInternational journal of molecular sciences2024
Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements.
Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 2 syntheses or guidelines pooled it, 112 citations in OpenAlex.
- The role of ultrasound-guided tru-cut biopsy in ovarian cancer: a systematic review of its safety, adequacy, and accuracy with meta-analysis of diagnostic performance.Journal of ovarian research · 2025Pooled it
- Comparative effectiveness and safety of immunotherapeutic strategies in ovarian cancer: a systematic review and network meta-analysis.Frontiers in oncology · 2025Pooled it
- Two-step PEG-based surface functionalization of gold nanoparticles enables specific SERS imaging of EGFR in an ovarian cancer cell model.Materials today. Bio · 2026Article
- SMS1 and SMS2 differentially regulate platinum chemotherapy sensitivity in ovarian cancer cells.Molecular biology reports · 2026Article
- Breaking barriers in gynecologic malignancies with adoptive cell transfers and nanomedicine.Cell biomaterials · 2026Article
- The promising role of engineered T lymphocytes in immunotherapy for high-grade serous ovarian carcinoma: a review of mechanisms, clinical landscape, and future strategies.Journal of the Egyptian National Cancer Institute · 2026Review
- Cancer trends in England in younger adults from 2001-2023: comparing incidence, mortality and stage at diagnosis.medRxiv : the preprint server for health sciences · 2026Article
- Metronomic Chemotherapy in Ovarian Cancer: Current Scenario and AI-Integrated Future Strategies.Cancer reports (Hoboken, N.J.) · 2026Review
- LMTK3 as a spatially regulated and stage-dependent biomarker in epithelial ovarian tumorigenesis.Molecular therapy. Oncology · 2026Article
- Bilateral ovarian serous cystadenocarcinoma with peritoneal dissemination and a coexisting cervical mass: A diagnostic dilemma.Radiology case reports · 2026Article
- Prevalence of Homologous Recombination Deficiency and Treatment Patterns in Patients with Newly Diagnosed Advanced Ovarian Cancer in Bulgaria: A Real-World Cohort Study (VALIDATE).Medicina (Kaunas, Lithuania) · 2026Observational
- Exploring the somatic mutational landscape of ovarian cancer in Estonia.Acta oncologica (Stockholm, Sweden) · 2026Article
- Heparanase (HPSE) genetic variants as prognostic indicators in ovarian cancer: evidence from discovery and validation cohorts.Molecular biology reports · 2026Article
- From Seed to Therapy: Sesamin and Phytosterols of Sesamum indicum in Polycystic Ovary Syndrome and Ovarian Cancer.Reproductive sciences (Thousand Oaks, Calif.) · 2026Review
- Emerging Frontiers in Ovarian Organoids: Bridging Development,Function, and Disease Modeling: A Review.International journal of fertility & sterility · 2026Article
- Clinical validation of a DNA methylation biomarker associated with overall survival of relapsed ovarian cancer patients.International journal of cancer · 2026Article
- Clinical significance of CD27Journal of ovarian research · 2026Article
- Nanoparticle based siRNA therapeutics for ovarian cancer overcoming drug resistance and future directions.Discover nano · 2026Review
- Management of ocular toxicity in patients with gynecologic cancer receiving novel antibody-drug conjugates: a narrative review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- HMGB1 Assists in Overcoming Cisplatin Resistance in Chemoresistant Human Ovarian Cancer Cells.Molecular carcinogenesis · 2026Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Ovarian cancer (OC) is the female genital malignancy with the highest lethality. Patients present a poor prognosis mainly due to the late clinical presentation allied with the common acquisition of chemoresistance and a high rate of tumour recurrence. Effective screening, accurate diagnosis, and personalised multidisciplinary treatments are crucial for improving patients' survival and quality of life. This comprehensive narrative review aims to describe the current knowledge on the aetiology, prevention, diagnosis, and treatment of OC, highlighting the latest significant advancements and future directions. Traditionally, OC treatment involves the combination of cytoreductive surgery and platinum-based chemotherapy. Although more therapeutical approaches have been developed, the lack of established predictive biomarkers to guide disease management has led to only marginal improvements in progression-free survival (PFS) while patients face an increasing level of toxicity. Fortunately, because of a better overall understanding of ovarian tumourigenesis and advancements in the disease's (epi)genetic and molecular profiling, a paradigm shift has emerged with the identification of new disease biomarkers and the proposal of targeted therapeutic approaches to postpone disease recurrence and decrease side effects, while increasing patients' survival. Despite this progress, several challenges in disease management, including disease heterogeneity and drug resistance, still need to be overcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.